Open AccessDiabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin‐resistant Staphylococcus aureus
Author(s) -
Ambrosch Andreas,
Haefner Simone,
Jude Edward,
Lobmann Ralf
Publication year - 2011
Publication title -
international wound journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.867
H-Index - 63
eISSN - 1742-481X
pISSN - 1742-4801
DOI - 10.1111/j.1742-481x.2011.00849.x
Subject(s) - medicine , linezolid , tigecycline , methicillin resistant staphylococcus aureus , staphylococcus aureus , antibiotics , vancomycin , daptomycin , diabetic foot , fosfomycin , antibiotic resistance , microbiology and biotechnology , intensive care medicine , diabetes mellitus , bacteria , biology , endocrinology , genetics
Diabetic patients are at increased risk of complicated skin, skin structure and bone infections including infections of diabetic foot ulcerations (DFU). Analyses of epidemiology and microbial pathogenicity show that staphylococci seem to be predestined to induce such infections. In addition, multidrug resistance particularly due to an increasing prevalence of methicillin‐resistant Staphylococcus aureus (MRSA) seems to be the challenge for effective antibiotic therapy. With regard to infections with MRSA, classical agents like vancomycin, linezolid, fosfomycin or trimethroprim–sulphametoxazol might be agents of choice in DFU. New‐generation drugs including broad‐spectrum tetracyclines like tigecycline, first and second generation of cyclic lipopeptides, anti‐MRSA β ‐lactams including ceftobiprole and anti‐MRSA antibodies are developed or in progress and the hope for the future.